NCT03552575View on ClinicalTrials.gov

The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

July 25, 2020

Study Completion Date

July 25, 2020

Conditions
Heart Failure
Interventions
DRUG

sacubitril/valsartan

Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

DRUG

Valsartan

is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.

Trial Locations (2)

G12 8TA

Glasgow Cardiovascular Research Centre, Glasgow

G51 4TF

Glasgow Clinical Research Facility, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER

NCT03552575 - The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI | Biotech Hunter | Biotech Hunter